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1. Introduction
In this chapter, we will explore the effect of human leukocyte antigen (HLA) matching on renal
transplant outcomes. The importance of HLA matching has been clearly established in renal
transplantation and the extent of HLA mismatches at the A, B and DR loci form an important
part in the assessment of the immunological risk of potential transplant candidates. Increasing
number of HLA mismatches has been shown to be associated with poorer graft and patient
survival following kidney transplantation but the ongoing importance of this association in
the era of more potent immunosuppression and improved donor selection remains unclear.
Nevertheless, HLA mismatches remain a crucial component of deceased donor kidney
allocation in most countries including the United States and Australia. As a result of major
advances in technology, HLA-typing has evolved from serological-based typing to molecular
HLA-typing and solid-phase anti-HLA-antibody-detection assays, which have had a major
influence in both allocation and outcome of transplanted kidneys. The identification of donor-
specific anti-HLA-antibody (DSA) has become standard practice and cross-matching assays
to establish the presence of DSA has evolved from complement-dependent cytotoxicity (CDC)
assay to the exquisitely sensitive flow-cytometric and solid-phase assays. The availability of
these sensitive assays has enable clinicians to perform calculated panel reactive antibody and
virtual cross-match, which has led to a more accurate assessment of immunological risk of
potential transplant candidates and improvement in the allocation of deceased donor kidneys.
Defining the appropriate threshold values for clinically relevant DSA assignment, the ongoing
significance of HLA-matching in the presence of DSA and the importance of anti-HLA-Cw,
HLA-DQ and HLA-DP antibodies remain poorly defined. Finally, we will discuss the process
of identifying acceptable HLA-mismatches using HLAMatchmaker, which determines HLA-
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compatibility at the level of polymorphic amino acid triplets or eplets in antibody-accessible
regions, and the benefit of acceptable HLA-mismatch programs in improving the transplant
potential of highly sensitized transplant candidates.
2. Basic transplant immunology
Immune protection against foreign antigens in humans relies on a coordinated response of
both innate and adaptive immune system [1]. The innate system, comprising of anatomical
barriers (e.g. skin), phagocytic cells (e.g. macrophages), and soluble compounds (e.g. comple‐
ments and interferons [IFN]) provide an efficient initial defence against foreign antigens such
as donor antigens in solid organ transplantation but this response lacks specificity. In contrast,
subsequent adaptive immune response has the ability to create a large diversity of antigen-
specific responses upon antigenic challenge to the host, with the development of immunolog‐
ical memory consequent on subsequent exposure to the same antigen. This response involves
predominantly lymphocytes and antibodies, and is characteristically more intense, leading to
a more rapid elimination of the foreign antigen (Figure 1).
Foreign Antigens 
(donor-derived 
MHC peptides)
The ability of dendritic cells to coordinate innate and adaptive immune system. Upon exposure to foreign anti‐
gens, dendritic cells secrete pro-inflammatory cytokines ± cell-cell contact, activate effector cells including natural kill‐
er cells and macrophages (innate immunity). Immature dendritic cells capture and process antigens for presentation
to T cells via major histocompatibility complexes. DC undergo maturation and migrate to secondary lymphoid tissues
(enhanced by inflammatory cytokines produced by natural killer cells and CD40 ligand expressed by activated T cells).
Mature dendritic cells drive the expansion of antigen-specific, major histocompatibility complex-restricted T and B cell
responses and the development of immunologic memory (adaptive immunity).
Figure 1. Innate and adaptive immune response to foreign antigens.
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2.1. Dendritic cells (Figure 2)
Dendritic cells (DC) are a group of rare, heterogenous population of professional antigen-
presenting cells (APC) that can initiate primary immune responses, and hence have the ability
to regulate both innate and adaptive immune responses [2-4]. Precursor DC (pre-DC), arising
from bone marrow progenitors, enter tissues as immature DC with superior phagocytic
capabilities. DC encounter foreign antigens such as donor antigens (in solid organ transplan‐
tation), bacteria and tumour antigens resulting in the secretion of cytokines (e.g. IFN) and
activation of natural killer (NK) cells, macrophages and eosinophils. Following antigen capture
and processing, DC undergo maturation and migrate to secondary lymphoid tissues where
they present processed antigen/peptide coupled to major histocompatibility complexes (MHC)
to T cells, allowing for selection and expansion of antigen-specific cluster designation (CD)4+
T-helper cells. These CD4+ T-helper cells subsequently amplify the immune responses by
regulating antigen-specific (e.g. CD8+ cytotoxic T cells, B cells), and antigen non-specific (e.g.
macrophages, NK cells, and eosinophils) effector cells.
Stimulus (e.g. donor-derived 
MHC peptides)
Overview of the complex relationship between dendritic cells and effector T and B cells. Immature DC (MDC and
PDC) maturate in response to appropriate stimuli (e.g. microbial products, TLR ligands). Mature DC secretes immunor‐
egulatory cytokines (including IFN-α and IL-12] and with cell-cell contact, modulates effector cell response including
NK cells, B and T cells as well as providing a positive feedback to DC to initiate ongoing activation and maturation.
Activated effector cells could in turn modulate DC activation, maturation, and survival as well as enhancing other ef‐
fector cell functions through the production of cytokines (IFN-γ) and/or via cell-cell contact.
Figure 2. Interaction between dendritic cells and effector T and B cells.
DC play a critical role in the initiation and regulation of adaptive T cell responses, the main‐
tenance of central and peripheral tolerance in normal steady-state and hence are essential in
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regulating immune responses in solid organ and cellular transplantation. DC have dual roles
in organ transplantation. They are responsible for allorecognition and presentation of foreign
antigens to T cells, which may initiate allograft rejection; but are also involved in the promotion
of transplant tolerance.
2.2. Role of T and B cells in allograft rejection
2.2.1. T cells
The most common form of acute rejection of allogeneic tissues and allografts involve the
activation of recipient’s T cells (i.e. adaptive immune response) directed against donor MHC
antigens or MHC-derived peptides presented by either the donor’s or recipient’s APC [5]. DC
are considered the most potent form of APC in humans through their capacity for antigen
uptake and processing of foreign antigens into peptides which can then be presented to
antigen-specific T cells via MHC complexes, leading to activation and clonal expansion of naïve
and memory T cells (i.e. primary and secondary immune responses) [2]. During steady state,
DC reside as functionally immature cells in most tissues. Following organ transplantation, the
systemic effects of donor brain death and/or ischaemia-reperfusion injury are sufficient to
generate an inflammatory response to mature these DC during their migration carrying donor
antigens from the transplanted organ to the recipient’s secondary lymphoid organs including
the draining lymph nodes and spleen [6, 7]. DC may also be activated via CD40-CD40L
interaction, with activated cells (e.g. platelets, T cells, mast cells) within transplanted allografts
the potential source of CD40L. This interaction may regulate DC migration possibly via tumour
necrosis factor (TNF)-α production by DC [8]. DC maturation and immunostimulatory
capacity are dependent on nuclear factor kappa B (NF-κB)-dependent gene transcription
including genes involved in the expression of adhesion molecules, chemotactic factors and the
production of various cytokines [9]. Although DC are very efficient in presenting donor
antigens to T cells, other cell types including tubular epithelial cells, endothelial cells, macro‐
phages and also B cells can participate in T cell interaction, the latter by capturing and
presenting foreign antigens via their surface immunoglobulins and MHC class II molecules
[10-12].
Direct and indirect allorecognition of allogeneic antigens are mediated by donor-derived and
recipient’s DC respectively. Donor DC present donor peptide mounted on donor MHC
molecules to recipient’s T cells following migration of donor DC to T cell areas of lymphoid
tissues (‘passenger leukocytes’) in response to surgery [13]. This mode of presentation is
termed direct allorecognition and is particularly important in the initiation of acute rejection
resulting from a powerful alloantigen-specific T cell response directed against allogeneic
antigens [14]. The finding of >90% of infiltrating recipient’s T cells involved in recognising
donor-derived MHC molecule directly presented by donor DC during acute rejection of
allogeneic skin graft in mice support the existence of this direct pathway [15]. Furthermore,
the frequency of direct donor-specific hyporeactivity is similar between long-term renal
transplant recipients with good graft function compared to those recipients with established
chronic rejection suggesting that direct allorecognition is not the predominant response in
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chronic rejection [16]. In contrast, recipient’s DC may acquire allogeneic donor antigens
following migration into the allograft in response to proinflammatory cytokines and chemo‐
kines. Recipient’s DC present donor MHC-derived peptides (e.g. regions of MHC class II
molecules) loaded to self-MHC molecule to recipient’s T cells. This mode of presentation is
termed indirect allorecognition and may be more important in establishing chronic rejection.
Unlike direct allorecognition, indirect allorecognition involves a less potent T cell response
with a reduced proportion of recipient’s T cells involve in the immune response directed
against the donor-derived antigens [17, 18]. The finding of a higher frequency of T cells with
indirect anti-donor reactivity in transplant recipients with established chronic rejection
support this finding [16]. Similarly, studies in non-human primates demonstrated that
inhibition of direct anti-donor reactivity can prolong graft survival, but does not prevent late
graft loss to chronic rejection [19]. In both direct and indirect allorecognition pathways, DC
can internalise extracellular donor antigens, process them and present them to either CD4+ or
CD8+ T cells through MHC class I or II molecules respectively. However, the contribution of
direct and indirect pathway in acute and chronic allograft rejection remains controversial with
studies demonstrating that indirect pathway may also be important in the initiation of acute
rejection [20].
Following activation of naïve T cells, activated CD4+ T cells proliferate and differentiate into
different cell types with distinct cytokine profiles. Subtypes of helper T cells include type I
helper T (Th1], Th2 cells, Th17 cells and regulatory T (Treg) cells. Although Th1 cells may be
more important in allograft rejection by producing inflammatory cytokines capable of driving
a cellular immune response such as IFN-γ and interleukin (IL)-2, Th2 cells may also be involved
in rejection through the activation of eosinophils and promoting a humoral immune response
(via cytokines IL4, 5 and 13) [21, 22]. There is increasing evidence that Th17 cells contribute to
allograft rejection although the susceptibility of these cells to immune regulation remains
unclear [23]. Although Treg cells are capable of inducing immune tolerance in animal models
of transplantation, the role of these cells in humans remains unclear [24, 25]. Both CD4+ and
CD8+ T cells can mediate allograft injury either directly or indirectly through the production
of cytokines or by activating vascular endothelial cells. CD8+ T cells can directly cause cell
death by promoting caspase-induced cell apoptosis by releasing perforin and granzymes A
and B intracellularly or via Fas-ligand/Fas-receptor interaction between CD8+T cells and
allograft [26]. Similarly, CD4+ T cells can directly induce cell apoptosis via Fas-ligand/Fas-
receptor interaction but they can also cause indirect cell damage by secreting TNF-α and TNF-
β, which subsequently bind to TNF-receptors on endothelial or tubular cells resulting in cell
apoptosis [27, 28].
2.2.2. B cells
There is increasing evidence that in solid organ transplantation, B cells play an important role
in the immune response to an allograft through the production of antibodies (resulting in the
development of acute and chronic antibody mediated rejection [AMR]), but these cells may
also have an important role in the support of T cells (resulting in the development of acute
cellular rejection) [29]. Most peripheral B cells are produced in the bone marrow and contin‐
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uously circulate as immature cells through secondary lymphoid organs until they encounter
antigen. Once activated, B cells become efficient APC by capturing antigen via B-cell receptor,
then interacts with naïve T cells through the presentation of antigen by MHC class II molecules
to T-cell receptor respectively. Through this interaction coupled with the ability to produce
cytokines such as IL-2, B cells are critical for optimal T cell activation and development of T
cell memory [30, 31]. Activated B cells may also differentiate into memory B cells or plasma
cells, a small proportion of the latter cell type may persist as long-lived plasma cells that reside
in the bone marrow ± allografts indefinitely, continuously producing IgG antibodies [32]. APCs
such as DC, monocytes and macrophages produce BAFF (B-cell-activating factor belonging to
the tumour necrosis factor family), a cytokine which enhances B cell survival [33]. Antibodies
produced by terminally differentiated B cells, especially directed against donor antigens, are
critical mediators of AMR and associated graft damage through complement activation and
Fc-receptor cross-linking, the latter resulting in proinflammatory cytokine release, DC
maturation, macrophage phagocytosis and NK cell-mediated antibody-dependent cellular
cytotoxicity [34]. Like Treg cells, there is a recently described subset of B cells in humans and
mouse known as regulatory B cells, which are capable inhibiting T cell responses, possibly
through the production of IL-10 [35]. The clinical significance of these regulatory B cells in
organ transplantation remains unclear.
3. Human Leukocyte Antigen (HLA)
The HLA system is the name given to the human MHC, which was first described by Jean
Dausset in 1952 after observing the development of alloantibodies to leukocytes following
blood transfusions [36]. The HLA system comprises a group of cell-surface antigen-presenting
proteins encoded by a region on the short arm of chromosome 6 and is divided into class I and
class II molecules. Humans have three class I HLA (A, B, C) that are present on all nucleated
cells and six class II HLA (DPA1, DPB1, DQA1, DQB1, DRA, DRB1) that are present only on
antigen-presenting cells and lymphocytes. Class I HLA presents intracellular antigens while
class II HLA present extracellular antigens. HLA are highly polymorphic with almost 6000
HLA Class I and over 1500 HLA Class II alleles having been identified [37]. Three of the seven
heterodimers (HLA-A, -B, and -DRB1) contribute to the majority of the immunogenicity of
mismatched antigens and therefore traditional HLA-typing methods have primarily focussed
on these alleles.
HLA play an important role in the immune system by controlling immune responses through
antigen presentation and distinguish “self” from “non-self”. Since its introduction after the
first International Histocompatibility Workshop (IHWS) in 1964, HLA matching has formed
the cornerstone of deceased-donor kidney allocation policies worldwide [38]. By the first
World Health Organization nomenclature meeting in 1970, 27 HLA antigens were identified.
The discovery of new antigens on occasion splits previously known ‘broad’ antigens into two
or more antigens, termed ‘split’ antigens. For example, the A9 broad antigen was split to A23
and A24 split antigens, whereas the DR2 broad antigen was split to DR15 and DR16 split
antigens [39]. HLA matching criteria may vary with regards to consideration of broad or split
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antigens. Split antigen matching appears to be more common and clinically important for
HLA-A and-B antigens than for HLA-DR antigens [40]. Not surprisingly, utilization of
matching for broad antigens increases the probability of identifying HLA-matched recipients
for any given donor [41].
Although 0 HLA-mismatched grafts have been shown to have superior graft outcomes
compared with grafts with ≥1 HLA-mismatch, a proportion of 0 HLA-mismatched grafts may
be complicated by acute rejection, possibly reflecting potential allorecognition of incompati‐
bilities at other minor HLA loci. On the contrary, many HLA-mismatched grafts have excellent
graft outcomes without acute rejection, suggesting that under specific circumstances, certain
HLA mismatches may be permissible, such as the lack of immunologic response against non-
inherited maternal HLA antigens (NIMA) as a result of prenatal tolerance development.
However, verification of this association between NIMA and graft outcomes remains incon‐
clusive [42-44].
HLA compatibility has also been defined by mismatch acceptability known as acceptable HLA-
mismatch. These are mismatched HLA antigens that do not result in a positive complement
dependent cytotoxicity (CDC) crossmatch [42]. Identification of acceptable HLA-mismatches
has been utilised to improve the transplant potential of highly sensitized patients, and this
concept and application will be discussed in greater details later in this chapter.
In most countries worldwide including Australia, the number of HLA-mismatches is calcu‐
lated by the sum of the total number of HLA-mismatches between donor-recipient at HLA-A,
B, and DR loci. Large single centre and registry studies have consistently demonstrated an
inverse association between increasing number of mismatches and graft and/or patient
survival [43-45]. However, with the evolution from serological to molecular-based HLA-
typing over time resulting in improved immunological risk stratification of transplant
candidates, coupled with the availability of more potent immunosuppression and donor
selection has created uncertainty regarding the ongoing clinical importance of HLA-mis‐
matches in the modern era.
4. Effect of HLA-mismatches and renal transplant outcomes
Large registry reports including analysis from the Collaborative Transplant Study (CTS) and
more recently from the Australia and New Zealand Dialysis and Transplant (ANZDATA)
registry have consistently demonstrated a strong association between HLA-matching at the
HLA-A, B and DR loci and graft and patient outcomes, independent of donor type, initial
immunosuppression, transplant era and even the presence of DSA [46-48].
The advantage of improved HLA-matching in reducing acute rejection risk has been demon‐
strated predominantly in renal transplant recipients receiving cyclosporine-based immuno‐
suppressive regimen [49, 50]. Recent retrospective single centre study of live and deceased
donor renal transplants has demonstrated that HLA-mismatches remained an important
determinant of acute rejection risk in renal transplant recipients receiving quadruple immu‐
The Evolution of HLA-Matching in Kidney Transplantation
http://dx.doi.org/10.5772/54747
351
nosuppression involving the use of interleukin-2 receptor antibody induction, tacrolimus,
mycophenolate mofetil and corticosteroids [51]. In this study, increasing number of HLA
mismatches was an independent predictor of acute rejection (OR 1.65 for every single HLA-
mismatch; 95% CI: 1.15 to 2.38; P=0.007), with HLA-mismatches at the HLA-DR locus associ‐
ated with the highest risk of acute rejection compared to mismatches at the HLA-A and HLA-
B loci in the adjusted model. Analysis of the CTS data of 135,970 deceased donor renal
transplant recipients demonstrated that the effect of HLA-mismatches on acute rejection risk
remained highly significant over two consecutive decades (1985-1994 vs 1995-2004), inde‐
pendent of ‘intention to treat’ immunosuppressive regimen [47]. Similarly, recent analysis of
ANZDATA registry of live and deceased donor renal transplants between 1998 and 2009
demonstrated that the association between HLA-mismatches and acute rejection risk appeared
to be independent of transplant era and initial immunosuppression, but this association
appeared to be much stronger for live-donor transplants compared to deceased donor
transplants (Figure 3A). The reduced benefit of 0-HLA-mismatched kidneys in recipients of
deceased compared with live donor kidneys may be explained by the presence in unrelated
deceased donors of apparently matched but actually mismatched splits of antigens, which is
less frequently observed in biologically related living donors [46]. However, the association
between HLA mismatches and rejection was not linear, with the greatest benefit of HLA
matching appeared to be confined to those with <4 HLA mismatches [46, 47].
Large retrospective studies have consistently demonstrated the importance of HLA-matching
in determining deceased donor renal allograft survival [52-54]. Analysis of the United Net‐
work for Organ Sharing (UNOS) registry between 1991 to 1997 demonstrated an 11% reduc‐
tion in 3-year graft survival rate (p<0.001) between transplants involving 6 compared to 0 HLA-
mismatches, with the most discernible difference in survival was observed between recipients
with 0 to 1 HLA-mismatch [55]. In the UNOS study, the association between HLA-mismatches
and reduced graft survival appeared to be related to mismatches at the HLA-DR locus within the
first year post-transplant, whereas mismatches at the HLA-AB loci were more important beyond
the first year post-transplant. However, the association between HLA-mismatches and graft
survival in the era of modern immunosuppression remains contradictory [56]. Analysis of the
CTS data demonstrated that the importance of HLA-matching on graft outcomes remained strong
during the two decades of 1985-1994 and 1995-2004, suggesting that association between HLA-
mismatches and graft survival remains robust in the era of modern immunosuppression [47].
Unlike the other large registry studies that had focused on deceased donor renal transplants, the
study by Lim WH et al using ANZDATA registry data evaluated both live and deceased donor
renal transplants. Similarly, the authors demonstrated a strong association between HLA-
mismatches and overall graft survival for both live and deceased donor renal transplants (Figure
3B), especially between those receiving 0-HLA-mismatched kidneys compared to those receiving
≥1 HLA-mismatched kidneys [46]. In contrast, analysis of the UNOS data suggested that the
relative importance of HLA-mismatches and reduced graft survival may have diminished in
recent years, whereas other factors such as donor age retained their statistical significance over
time prompting the suggestion that kidney allocation algorithms based predominantly on HLA-
matching should be modified [57]. However, this study focused on era between 1994 and 1998
whereby the use of induction therapy and/or tacrolimus was limited.
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Figure 3. (a) Odds ratio plot of HLA mismatches and acute rejection according to donor type (reference live donor 0
HLA mismatch) and corresponding table of the adjusted odds ratio between HLA mismatches and acute rejection ac‐
cording to donor type (reference live or deceased donor 0 HLA mismatch; adapted from Lim WH et al Clin Transplant
2012) [46]. (b) Kaplan–Meier survival curve of overall graft failure according to the number of HLA mismatches with
corresponding numerical table of the number at risk at 0, 4 and 8 years post-transplant (adapted from Lim WH et al
Clin Transplant 2012) [46].
The association between acute rejection and graft survival appears well established. In the
study by Wissing et al, the authors had shown rejection within the first year post-transplant
was independently associated with a significant reduction in overall (57% vs 83%; p=0.0004)
and death-censored graft survival (63.5% vs 91.2%; p<0.0001) [51], a finding corroborated by
ANZDATA registry analysis [46].
Although HLA-DR mismatches appear to be of greater importance in predicting graft
outcomes compared to HLA-AB mismatches, the current kidney allocation algorithm in
Australia specifically favours fully HLA-DR matched recipients but still takes into account
HLA-AB matching, therefore confers an appropriate concession to allow satisfactory HLA-
matching but avoiding discrimination to potential recipients with rare HLA combinations as
HLA-DR locus has fewer polymorphisms compared to HLA-AB loci [58]. Previous studies
have demonstrated that allocation based predominantly on HLA-DR matching, as imple‐
mented in the United States, may eliminate any advantage of HLA-AB matching but this
remains controversial [59, 60]. Analysis of Scientific Registry of Transplant Recipients (SRTR)
of 108,701 deceased donor renal transplant recipients demonstrated that the elimination of
allocation priority for HLA-B mismatches improved the transplant potential of ethnic minor‐
ities and this policy had achieved comparable renal allograft survival compared to historical
graft outcomes prior to the change in allocation policy [61]. Although the presence of HLA-
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Cw, DP and DQ DSA have been shown to be associated with poorer graft outcomes [62, 63],
matching at the HLA-Cw, DP and DQ loci are not routinely performed and therefore is not
explicitly included in the allocation of deceased donor kidneys in any countries.
5. Serological and molecular HLA typing and the detection of donor-
specific anti-HLA antibodies (Figure 4)
The evolution in our understanding of the HLA system is closely linked to advancements in
technology. Traditional serological-based low resolution HLA typing methods can be com‐
pleted relatively quickly but are dependent on the availability of specific cell types, viability
and appropriate anti-sera that are capable of recognising HLA antigens. The emergence of
molecular HLA typing techniques over the past two decades has allowed for a more specific,
flexible and robust means of high resolution HLA typing. In 1982, Wake et al described
restriction fragment length polymorphism (RFLPs), which eventually highlighted the short‐
comings of serology-based methods ensuing the establishment of molecular-based HLA-
typing for routine clinical practice [64]. Data generated via the genome project and the
initiation of polymerase chain reaction (PCR) techniques through the 1980s further refined
DNA-based techniques for HLA-typing, which has led to the development of a number of
PCR-based techniques still in use to the present day.
Alongside advances in the typing of HLA alleles, the techniques used to detect anti-HLA
antibodies has also evolved from CDC assays to more sensitive techniques including flow-
cytometry  and solid-phase  assays  (e.g.  enzyme-linked immunosorbent  assay  [ELISA]  or
Luminex), which has allowed a more accurate assessment of transplant candidate’s immunolog‐
ical risk pre-transplantation (e.g. calculated panel reactive antibodies to determine level of
sensitization and application of virtual cross-match to determine transplant suitability) (Figure 4).
Since the recognition of the clinical importance of CDC assay in kidney transplantation in the
1960s, CDC cross-match has become the cornerstone of determining transplant suitability in
both live and deceased donor renal transplantation [65]. The underlying principle of CDC
cross-match is to detect clinically relevant donor-specific anti-HLA antibodies that could result
in hyperacute rejection following transplantation. Donor T and B cells are incubated in the
presence of recipients’ sera and complements. If donor-specific anti-HLA antibodies are
present, these will bind to donor cells and initiate the complement cascade resulting in lysis
of donor lymphocytes. The percentage of lysis will be quantified and forms the basis of
determining transplant candidate’s suitability for transplantation. Many laboratories perform
CDC assays in the presence of anti-human globulin (enhances the sensitivity of assay by
enhancing the number of Fc receptors available to bind with complements) and/or dithio‐
threitol (breaks down the disulfide bonds in IgM antibodies of no clinical significance) to
improve the accuracy and reduce the false negative rates associated with these assays [66, 67].
Initial data using the CDC assay revealed that 80% of CDC cross-match–positive transplants
and 4% of CDC cross-match–negative transplants were associated with early graft loss (within
48 hours post-transplant), thereby establishing the clinical significance of anti-HLA antibodies
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in renal transplantation. The inability to correlate all graft losses with anti-HLA antibodies has
led to the development of more sensitive cross-match assays, including flow cytometric cross-
match assays. It is noteworthy that 20% of patients transplanted across a positive cross-match
did not lose their grafts [68]. Because T cells express class I antigens and B cells express both
class I and II antigens, the interpretation of T cell together with B cell cross-match will help to
establish whether class I and/or II anti-HLA antibodies are present. A positive B cell CDC cross-
match invariably accompanies a positive T cell CDC cross-match but this may reflect either
anti-HLA antibodies to class I antigens and/or multiple antibodies to class I and/or II antigens.
However, a positive B cell CDC cross-match may occur in the absence of a positive T cell CDC
cross-match and suggest the presence of class II antigens or low levels class I antigens. The
presence of a positive T cell CDC cross-match is an absolute contraindication for transplanta‐
tion whereas a positive B cell cross-match is a relative contraindication because of the uncer‐
tainty regarding the clinical significance and the possibility of false-positive results [69, 70]. In
the allocation of deceased donor kidneys in Australia, the presence of a positive T cell CDC
 
 
 
Cell-based assays Solid-phase assays 
• CDC-XM reduced the incidence of hyperacute 
rejection 
• Inability to identify the antigen causing positive 
• Sensitive with high degree of specificity to donor 
antigens, luminex more sensitive than ELISA 
• Capable of quantifying anti-HLA antibodies level  
HLA – human leukocyte antigen, CDC-XM – complement-dependent cytotoxicity cross-match, ELISA – enzyme-linked
immunosorbent assay.
Figure 4. Detection of anti-HLA antibodies – differences between cell-based and solid-phase assays.
The Evolution of HLA-Matching in Kidney Transplantation
http://dx.doi.org/10.5772/54747
355
cross-match is an absolute contraindication for transplantation whereas B cell cross-match is
not routinely performed and therefore not utilized in the decision-making process for trans‐
plantation. With the increasing recognition of the potential importance of a positive CDC B
cell cross-match, these results are now often interpreted in the context of solid phase assays.
The basic principle of flow cross-match technique is similar to CDC assay. Since the description
of this assay in the early 1980s, this technique has been widely adopted to determine transplant
suitability [71]. Similar to CDC assay, flow assay requires the addition of donor cells to
recipients’ sera, followed by the addition of a secondary fluorescein-labelled antibody allowing
for the detection by flow cytometry and quantification of antibodies expressed as channel
shifts. Unlike CDC cross-match, flow cytometric cross-match identifies both complement-
fixing and non-complement-fixing anti-HLA donor-specific antibodies. However, the availa‐
bility of different subtypes of detection antibodies has allowed for the differentiation between
complement-fixing versus non-complement-fixing antibodies [72]. Although an universal cut-
off value for a positive flow cross-match has not been determined, it is agreed that the use of
a low cut-off point will result in increased sensitivity but reduced specificity for predicting
graft outcomes (especially in the presence of negative CDC cross-match) as this may identify
anti-HLA donor specific antibodies of no clinical significance. Nevertheless, renal transplant
recipients with positive flow cross-match but negative CDC cross-match have a significantly
greater risk of antibody-mediated rejection (AMR) and early graft loss with a positive predic‐
tive value for predicting AMR of 83% [72, 73].
To avoid problems associated with the viability of the donor cells, which could affect the
accuracy of cell-based assays, the introduction of solid-phase assays have largely circumvented
these problems and improved the sensitivity of detection of anti-HLA antibodies [74]. The
identification of anti-HLA antibodies using ELISA was first described in 1993 where purified
HLA antigens were directly immobilized on the surface of microtitre plates but the basic
principle of antibody detection was similar to cell-based assays [75]. The Luminex platform is
a solid-phase assay that utilizes polystyrene microspheres (beads), each embedded with
fluorochromes of differing intensity attached to one (single-antigen beads) or several HLA
molecules (screening beads) to determine anti-HLA antibody specificity. Similar to other
assays, the addition of recipients’ sera containing anti-HLA antibodies are added to the bead
mix, these antibodies will bind to the appropriate beads expressing specific antigen(s). A
second phycoerytherin-labelled anti-human IgG is then added to this mixture and these
antibodies will bind to the primary anti-HLA antibody already attached to the beads. The
sample is then passed through lasers, which would independently excite the beads and the
phycoerytherin therefore allowing the laser detector to define antibody specificity [76, 77].
Unlike the CDC assays, Luminex assay detect both complement-fixing and non-complement-
fixing anti-HLA antibodies but does not detect IgM autoantibodies or non-HLA antibodies.
With the continued reliance on using cell-based cross-match assays, especially CDC cross-
match assays to determine transplant suitability, a potential disadvantage of virtual cross-
match is that transplants may be excluded based on antibody results with unknown clinical
relevance [78]. It is generally accepted that solid phase virtual cross-match to identify anti-
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HLA donor specific antibodies complements the results of cell-based assays to help inform
decision-making process with regards to transplant suitability.
6. Clinical significance of anti-HLA donor-specific antibodies
It is well known that the presence of high levels of pre-transplant class I (HLA-A and B) ± II
(HLA-DR) donor-specific antibodies (DSA; i.e. anti-HLA antibodies with reactivity against the
potential donor leading to positive cross-match often as a result of prior sensitization events
including previous HLA-mismatched transplants, blood transfusions or pregnancy) is
associated with poorer graft outcomes, including the development of acute AMR, chronic
AMR, transplant glomerulopathy and late graft loss (Table 1) [79-81]. However, few studies
have suggested that the association between pre-transplant DSA and graft survival was
restricted to recipients who had developed early AMR, within the first 30-days post-trans‐
plantation [82]. In addition, the authors queried the cost-effectiveness of pre-transplant
screening for preformed DSA by demonstrating that the additional cost associated with
quarterly screening for anti-HLA antibodies would be between 3200 to 6700 Euros, which
would equate to an additional 83,000 to 130,000 Euros per avoided AMR because of preformed
non-lymphocytotoxic DSA in transplant candidates on the transplant wait-list for >5 years [82].
There is also increasing evidence demonstrating that the development of de novo DSA (occur‐
ring post-transplantation), especially development of DSA directed against HLA-DQ graft
molecules in HLA-class II incompatible graft transplantations, are both associated with acute
and subclinical AMR and graft loss in kidney transplant only and/or simultaneous pancreas-
kidney transplant recipients [80, 83-85]. Although there is no current consensus on the level
of clinically significant DSA identified by flow cytometric or Luminex assays, most studies
have demonstrated that increasing single, peak or total DSA levels were associated with an
incremental risk of rejection and/or graft loss [86, 87]. Recent studies have suggested that the
detection of C1q-fixing DSA (i.e. the potential to identify DSA that can activate complements
by binding C1q) may be more specific in predicting acute rejection, biopsy C4d-deposition,
transplant glomerulopathy and late graft failure following kidney transplantation but this
remains controversial and not routinely performed in many transplanting centres [88, 89]. The
clinical benefit of routine regular surveillance for de novo DSA in improving graft survival
following kidney transplantation remains unclear although a recent study of 72 live-donor
renal transplant recipients suggested that the appearance of de novo DSA was inversely
proportional to the amount of maintenance immunosuppressive drugs (especially in the
weaning phase of immunosuppression minimization particularly prednisolone) such that
DSA monitoring may be highly effective for detecting escape from tolerance and reappearance
of the immune response in weaned patients [90]. With the greater understanding of HLA
antigens and anti-HLA antibodies, innovative techniques have been established to allow
transplantation across positive CDC and/or flow cross-match barriers but this is beyond the
scope of this chapter.
The Evolution of HLA-Matching in Kidney Transplantation
http://dx.doi.org/10.5772/54747
357
Study Cohort Rejection Graft survival
Eng H et al (n=471
DD renal transplant
recipients) [79]
83 T-B+ XM vs 386 T-B-
XM; IgG HLA DSA in 33%
of T-B+ XM patients
Vascular: 19% T-B- vs 32% T-B+
(p=0.01); DSA was a significant
predictor for vascular or
glomerular rejection
Graft loss: T-B+ - 44%; T-B- 27%
(especially class I DSA)
Lefaucheur C et al
(n=402 DD renal
transplant recipients)
[80]
83 (21%) positive DSA by
Luminex by peak sera vs
76 (19%) by current sera
The presence of SAB HLA-DSA on
the peak and current serum has a
PPV for AMR of 35% and 32%
respectively. Prevalence of AMR
1% in patients with MFI <465,
19% MFI between 466 and 3000,
36% MFI between 3001 and
6000, and 51% MFI "/>6000.
Peak HLA-DSA Luminex MFI
predicted AMR better than
current HLA-DSA MFI.
5 and 8-year DCGS were 89% and
84% in non-sensitized patients, 92%
and 92% in sensitized patients with
no peak HLA-DSA, and 71% and
61% in patients with peak HLA-DSA.
Relative risk (RR) for graft loss for
patients who had an episode of
AMR was 4.1 (95% CI 2.2 to 7.7) as
compared with patients without
AMR.
Lefaucheur C et al
(n=237 LD and DD
renal transplant
recipients) [81]
All negative T and B-cell
CDC-XM. 27% class I or II
anti-HLA antibody with
52% DSA.
The incidence of AMR among
patients with preformed DSA was
35%, 9-fold higher than in
patients without DSA (3%) (p <
0.001).
Overall graft survival at 8 years was
68% in patients with DSA and 77%
in those with no DSA. Graft survival
of patients with DSA and AMR was
significantly worse than in DSA
patients without AMR and in non-
DSA patients.
Amico P et al (n=334
LD and DD renal
transplant recipients)
[105]
332 negative T and B cell
CDC-XM, 67 DSA vs 267
no DSA by Luminex
Overall incidence of clinical/
subclinical rejection (i.e., AMR
and acute T-cell mediated
rejection) at day 200 post-
transplant was significantly
higher in patients with HLADSA
(48/67; 71%) than in patients
without HLA-DSA (94/267; 35%).
DCGS at 5 years was 89% in those
without DSA, 87% with DSA but no
AMR and 68% with DSA and AMR.
HLA – human leukocyte antigen, DD – deceased donor, LD – live-donor, CDC-XM – complement dependent cytotoxicity
cross-match, DSA – donor-specific antibodies, SAB – single antigen bead, AMR – antibody mediated rejection, DCGS –
death-censored graft survival, MFI – mean fluorescent intensity, PPV – positive predictive value.
Table 1. Association between donor-specific antibodies and graft outcomes.
7. HLA-matching in kidney allocation from deceased donors
Most renal transplant programs preferentially allocate kidneys from deceased donors to
transplant candidates with favourable HLA compatibility. The current allocation of deceased-
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donor kidneys in most countries, including Australia and the Eurotransplant group (Germany,
The Netherlands, Belgium, Luxembourg, Slovenia, and Austria), is weighted largely on the
degree of mismatched antigens at the HLA-A, -B and -DR loci, with less emphasis on other
factors such as time on dialysis, prior sensitization and even ischaemic time. When a potential
deceased-donor kidney is available in Australia, transplant candidates on the wait-list are
ranked according to an allocation score calculated from a combination of factors including the
number of HLA-mismatches, age of recipient, degree of sensitization and time on wait-list [91].
Approximately 20% of deceased donor kidneys are allocated on a national level to highly
sensitized transplant candidates (around 20% of kidneys allocated) but the remaining 80% of
deceased donor kidneys are allocated through individual state allocation algorithms.
Despite efforts to achieve equity of access to transplantation in many countries, the inclusion
of HLA matching in the allocation of deceased donor kidneys is believed to disadvantage
transplant candidates with uncommon HLA phenotypes [92]. Consequently, indigenous
populations and ethnic minorities often have a much longer transplant wait-list time and are
less likely to receive well-matched kidneys [97-100]. The elimination of the allocation priority
for HLA-B mismatches has been shown to improve the transplant potential of ethnic minorities
but this approach has not been widely adopted by other countries [61].
In Australia, unacceptable class I HLA-mismatches are defined using the Luminex platform
and the presence of class I DSA against HLA-A and -B antigens with >2000 mean fluorescent
intensity (MFI) excludes transplant candidates from receiving these donor kidneys, independ‐
ent of the CDC-cross match results. At present, class II DSA is not explicitly considered in the
allocation of kidneys from deceased donors in Australia but many centres have already
adopted the policy of avoiding transplantation of kidneys into transplant candidates with high
levels of class II DSA.
8. Acceptable HLA-mismatch and highly sensitized transplant candidates
Highly sensitised transplant candidates (defined as those having a panel reactive antibody
[PRA] level of >80%) on the deceased donor transplant wait-list are less likely to receive donor
kidneys (greater likelihood of obtaining a positive complement-dependent cytotoxicity [CDC]-
cross-match result with any given donor) and have a much longer wait-list time compared to
unsensitized transplant candidates, resulting in a greater risk of mortality whilst remaining
on the transplant wait-list [93]. In Australia, highly sensitized transplant candidates represent
approximately 5% of the wait-listed candidates and are more likely to wait on average twice
as long as unsensitized transplant candidates despite an increase in the number of deceased
donors over time (202 donors in 2006 compared to 309 donors in 2010) [6].
Although HLA matching has traditionally been performed at the broad antigen level, a model
considering cross-reacting groups (CREGs) may increase the probability of identifying more
compatible kidneys for ethnic minorities and highly sensitized transplant candidates. HLA
antigens comprise of multiple serologic epitopes made of polymorphic amino acid residues,
and it is these structures and their conformation and position that determine antibody
The Evolution of HLA-Matching in Kidney Transplantation
http://dx.doi.org/10.5772/54747
359
accessibility, recognition, and subsequent reactivity [94]. Almost 200 class I and II epitopes
have been defined by Luminex technology [95]. Some epitopes are shared across different HLA
alleles while some are unique to single or more restricted numbers of HLA alleles. While there
are considerable differences in HLA antigen frequencies between different ethnic groups,
CREGs are more evenly distributed [96].
The concept of acceptable HLA-mismatch identifies mismatched HLA-antigens that could be
considered as compatible at a structural or functional level. It is based on the principle that
each HLA antigen is structurally unique and that an individual cannot mount an immuno‐
logical response against an epitope expressed by their own HLA, i.e. one cannot react against
shared ‘self’ epitopes [105, 106]. It has been demonstrated that such acceptable HLA-mis‐
matches would result in a negative CDC cross-match and therefore allow transplantation to
safely proceed [97, 98].
Acceptable HLA-mismatches can be identified using HLAMatchmaker or the Luminex
platform. HLAMatchmaker is a computer algorithm that regards each HLA antigen as a string
of polymorphic amino acid configurations in antibody-accessible positions (epitopes) formed
by triplets or eplets [99, 100]. For any given set of HLA antigens, HLAMatchmaker can define
the number of triplet or eplet mismatches present against any foreign HLA antigen and hence
define the HLA antigens that are mismatched at the broad antigen level but matched at the
eplet level, i.e. acceptable HLA-mismatches. Graft outcomes of HLAMatchmaker-identified
0-2 triplet-mismatched kidney transplant recipients are similar compared to recipients with 0
HLA-mismatch at the HLA-A, -B and –DR loci (Figure 5) [101]
HLA – human leukocyte antigen, UNOS – United Nation Organ Sharing, T - triplets.
Figure 5. Impact of HLA-A, -B triplet (T) matching on 5-year graft survival rates in zero-HLA-DR-mismatched kidney
transplants in a cohort of United Nation of Organ Sharing (UNOS) renal transplant recipients between 1987 and 1999
(adapted from Duquesnoy et al Transplantation 2003) [101].
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The Luminex platform determines specificity and quantifies anti-HLA antibodies present in
potential transplant candidates and is used in Australia to define unacceptable class I HLA-
mismatches. Although it may be logical to consider Luminex-define DSA with MFI of <500 as
acceptable mismatch, the utlilization of this technique or the appropriate thresholds of
Luminex-determined acceptable mismatch remain unknown [102].
In highly sensitized transplant candidates, the identification of acceptable HLA-mismatch has
been shown to improve their transplant potential by reducing the number of HLA-mismatches
therefore identifying additional donors likely to produce a negative CDC cross-match.
9. Acceptable HLA-mismatch programs
Successful acceptable HLA-mismatch programs have been implemented in many countries,
including Europe, United Kingdom and United States [45, 114-116]. Eurotransplant Acceptable
Mismatch Program was established in mid 1970 to improve the transplant potential of highly
sensitized transplant candidates. Over the ensuing decade, eleven other similar programs were
introduced throughout Europe [103]. Although there is considerable variation in PRA cut-off
to define highly sensitized transplant candidates, it is generally accepted that PRA >80% may
be the most appropriate cut-off. Table 2 highlights the results of the established acceptable
mismatch programs.
Scheme Initiation Reference Eligibility Outcomes/Activity
UK Transplant SOS Scheme
(UKT:SOS)
Feb 1984 [106] PRA"/>85%
(historic or
current sera)
• 65% graft survival at 1year
• 42% transplanted within 1year
Collaborative Transplant Study
Highly Immunized Trial
(CTS:HIT)
1985 [107] PRA"/>80%
(current sera)
• 5-year graft survival comparable to
unsensitized recipients (59% vs 60%)
Eurotransplant Acceptable
Mismatch Program
(ET:ACMM)
1985 [100] PRA≥85%
(historic or
current sera)
• 2-year graft survival comparable to
unsensitized recipients (87%)
• 45% transplanted in 1year, mean 8.9
months reduction in mean wait time
South Eastern Organ Procurement
Foundation High Grade HLA Match
algorithm
(SEOPF:HGM)
Jan 1994 [108] PRA≥40%
(current sera)
• 2-year graft survival comparable to
unsensitized recipients (86% vs 88%)
PRA – panel reactive antibody, HLA – human leukocyte antigen
Table 2. Description of allocation schemes based on acceptable HLA-mismatch.
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The Eurotransplant Acceptable Mismatch Program is the largest and most successful program
and runs in parallel with the Eurotransplant Kidney Allocation System (ETKAS) to identify
acceptable HLA-mismatches in potential highly sensitized transplant candidates through
comprehensive serum screening for acceptable mismatches. The introduction of the acceptable
mismatch program has significantly reduced waiting time for highly sensitized transplant
candidates whilst achieving comparable short and long-term graft outcomes to unsensitized
transplant recipients [100].
The deceased donor kidney allocation algorithm in Australia does not consider acceptable
HLA-mismatches for highly sensitized transplant candidates. We are currently investigating
the impact of identifying and incorporating acceptable mismatches into the deceased-donor
kidney allocation model and our preliminary data suggest that an acceptable mismatch
program could result in an improvement in transplant potential of 1 in 10 highly sensitized
renal transplant recipients (PRA >80%) with a potential reduction in average transplant wait-
list time of 33 months [104].
10. Conclusion
Despite the evolution of more sensitive molecular-based HLA-typing and the ability to detect
DSA, there continues to be an important association between HLA-matching and graft and
patient outcomes in kidney transplantation. Nevertheless, the application of molecular-based
typing in kidney transplantation is already being mandated by most of the transplant com‐
munity and may provide greater accuracy in the assessment of individual’s immunological
risk as well as improving transplant outcomes.
Author details
Hung Do Nguyen1,2, Rebecca Lucy Williams1, Germaine Wong3 and Wai Hon Lim1,2
*Address all correspondence to: wai.lim@health.wa.gov.au
1 Department of Renal Medicine, Sir Charles Gairdner Hospital, Australia
2 School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
3 Sydney School of Public Health, University of Sydney; Centre for Kidney Research, The
Children's Hospital at Westmead; Centre for Transplant and Renal Research, Westmead
Hospital, Sydney, Australia
Current Issues and Future Direction in Kidney Transplantation362
References
[1] Fearon D, Locksley R. The instructive role of innate immunity in the acquired im‐
mune response. Science 1996; 272 (5258): 50.
[2] Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Ann Rev Im‐
munol 2000; 18: 767.
[3] Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature
1998; 392: 245.
[4] Coates PTH, Thomson AW. Dendritic cells, tolerance induction and transplant out‐
come. Am J Transplant 2002; 2 (3): 299.
[5] Morelli A, Thomson A. Dendritic cells: regulators of alloimmunity and opportunities
for tolerance induction. Immunol Rev 2003; 196: 125.
[6] Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of
dendritic cells. Nat Med 1999; 5: 1249.
[7] Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Im‐
munol 2001; 13: 114.
[8] Morelli A, Zahorchak A, Larregina A, et al. Regulation of cytokine production by
mouse myeloid dendritic cells in relation to differentiation and terminal maturation
induced by LPS or CD40 ligation. Blood 2001; 98 (5): 1512.
[9] Rescigno M, Martino M, Sutherland C, Gold M, Ricciardi-Castagnoli P. Dendritic cell
survival and maturation are regulated by different signaling pathways. J Exp Med
1998; 188: 2175.
[10] Nankivell B, Alexander S. Rejection of the kidney allograft. N Engl J Med 2010; 363
(15): 1451.
[11] Hagerty D, Allen P. Processing and presentation of self and foreign antigens by the
renal proximal tubule. J Immunol 1992; 148: 2324.
[12] Kreisel D, Krupnick A, Balsara K, et al. Mouse vascular endothelium activates CD8+
T lymphocytes in a B7-dependent fashion. J Immunol 2002; 169 (11): 6154.
[13] Larsen C, Morris P, Austyn J. Migration of dendritic leukocytes from cardiac allog‐
rafts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990;
171: 307.
[14] Suciu-Foca N, Colovai A, Ciubotariu R, Cortesini R. Mapping of HLA-DR determi‐
nants recognized via the indirect pathway. Graft 1999; 2: 28.
[15] Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell al‐
loreactivity during allograft rejection in mice. J Immunol 1999; 162: 352.
The Evolution of HLA-Matching in Kidney Transplantation
http://dx.doi.org/10.5772/54747
363
[16] Baker R, Hernandez-Fuentes M, Brookes P, Chaudhry A, Cook H, Lechler R. Loss of
direct and maintenance of indirect alloresponses in renal allograft recipients: implica‐
tions for the pathogenesis of chronic allograft nephropathy. J Immunol 2001; 167 (12):
7199.
[17] Gould D, Auchincloss HJ. Direct and indirect recognition: the role of MHC antigens
in graft rejection. Immunol Today 1999; 20: 77.
[18] Lechler R, Ng W, Steinman R. Dendritic cells in transplantation - friend or foe. Im‐
munity 2001; 14 (4): 357.
[19] Montgomery S, Xu H, Tadaki D, et al. Combination induction therapy with monoclo‐
nal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal trans‐
plantation. Transplantation 2002; 74 (10): 1365.
[20] Auchincloss H, Lee R, Shea S, Markowitz J, Grusby M, Glimcher L. The role of "indi‐
rect" recognition in initiating rejection of skin grafts from major histocompatibility
complex class II-deficient mice. Proc Natl Acad Sci U S A 1993; 90: 3373.
[21] Zhai Y, Ghobrial R, Busuttil R, Kupiec-Weglinski J. Th1 and Th2 cytokines in organ
transplantation: paradigm lost? Crit Rev Immunol 1999; 19: 155.
[22] Goldman M, Le Moine A, Braun M, Flamand V, Abramowicz D. A role for eosino‐
phils in transplant rejection. Trends Immunol 2001; 22 (5): 247.
[23] Chadha R, Heidt S, Jones N, Wood K. Th17: contributors to allograft rejection and a
barrier to the induction of transplantation tolerance? Transplantation; 91 (9): 939.
[24] Wood K, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Im‐
munol 2003; 3: 199.
[25] Wood K, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev
Immunol 2012; 12 (6): 417.
[26] Barry M, Bleackley R. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Im‐
munol 2002; 2: 401.
[27] Al-Lamki R, Wang J, Skepper J, Thiru S, Pober J, Bradley J. Expression of tumor ne‐
crosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest
2001; 81: 1503.
[28] Jagger A, Evans H, Walter G, et al. FAS/FAS-L dependent killing of activated human
monocytes and macrophages by CD4+CD25- responder T cells, but not CD4+CD25+
regulatory T cells. J Autoimmun 2012; 38 (1): 29.
[29] Caltworthy M. Targeting B cells and antibody in transplantation. Am J Transplant
2011; 11: 1359.
[30] Ng Y, Oberbarnscheidt M, Chandramoorthy H, Hoffman R, Chalasani G. B cells help
alloreactive T cells differentiate into memory T cells. Am J Transplant 2010; 10: 1970.
Current Issues and Future Direction in Kidney Transplantation364
[31] Lund F, Randall T. Effector and regulatory B cells: modulators of CD4+ T cell im‐
munity. Nat Rev Immunol 2010; 10 (4): 236.
[32] Vinuesa C, Linterman M, Goodnow C, Randall K. T cells and follicular dendritic cells
in germinal center B-cell formation and selection. Immunol Rev 2010; 237: 72.
[33] Parsons R, Vivek K, Redfield Rr, et al. B-lymphocyte homeostasis and BLyS-directed
immunotherapy in transplantation. Transplant Rev 2010; 24 (4): 207.
[34] Smith K, Clatworthy M. FcgammaRIIB in autoimmunity and infection: Evolutionary
and therapeutic implications. Nat Rev Immunol 2010; 10: 328.
[35] DiLillo D, Matsushita T, Tedder T. B10 cells and regulatory B cells balance immune
responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010;
1183: 38.
[36] Dausset J. Les thrombo-anticorps: Acta Haematologica, 1958.
[37] EMBL-EBI. IMGT HLA sequence data.
[38] Bontadini A. HLA techniques: Typing and antibody detection in the laboratory of
immunogenetics. METHODS 2012: 1.
[39] Terasaki PI. Histocompatibility testing, 1980, 1980.
[40] Hata Y, Cecka JM, Takemoto S, Ozawa M, Cho YW, Terasaki PI. Effects of changes in
the criteria for nationally shared kidney transplants for HLA-matched patients.
Transplantation 1998; 65 (2): 208.
[41] Takemoto S, Terasaki P. Equitable allocation of HLA-compatible kidneys for local
pools and for minorities. New England Journal … 1994.
[42] Claas FHJ, Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis IIN. The ac‐
ceptable mismatch program as a fast tool for highly sensitized patients awaiting a ca‐
daveric kidney transplantation: short waiting time and excellent graft outcome.
Transplantation 2004; 78 (2): 190.
[43] Lim W, Chadban S, Clayton P, et al. Human Leukocyte Antigen Mismatches Associ‐
ated with Increased Risk of Rejection, Graft Failure and Death Independent of Initial
Immunosuppression in Renal Transplant Recipients. Unpublished: 1.
[44] Opelz G. Impact of HLA compatibility on survival of kidney transplants from unre‐
lated live donors. Transplantation 1997; 64 (10): 1473.
[45] Paramesh AS, Zhang R, Baber J, et al. The effect of HLA mismatch on highly sensi‐
tized renal allograft recipients. Clinical transplantation 2010; 24 (6): E247.
[46] Lim W, Chadban S, Clayton P, et al. Human leukocyte antigen mismatches associat‐
ed with increased risk of rejection, graft failure, and death independent of initial im‐
munosuppression in renal transplant recipients. Clin Transplant 2012; e-pub.
The Evolution of HLA-Matching in Kidney Transplantation
http://dx.doi.org/10.5772/54747
365
[47] Opelz G, Dohler B. Effect of human leukocyte antigen compatibility on kidney graft
survival: comparative analysis of two decades. Transplantation 2007; 84 (2): 137.
[48] Dunn T, Noreen H, Gillingham K, et al. Revisiting Traditional Risk Factors for Rejec‐
tion and Graft Loss After Kidney Transplantation. Am J Transplant 2011; 11 (10):
2132.
[49] Beckingham I, Dennis M, Bishop M, Blamey R, Smith S, Nicholson M. Effect of hu‐
man leucocyte antigen matching on the incidence of acute rejection in renal trans‐
plantation. Br J Surg 1994; 81 (4): 574.
[50] McKenna R, Lee K, Gough J, et al. Matching for private or public HLA epitopes re‐
duces acute rejection episodes and improves two-year renal allograft function. Trans‐
plantation 1998; 66 (1): 38.
[51] Wissing K, Fomegné G, Broeders N, et al. HLA mismatches remain risk factors for
acute kidney allograft rejection in patients receiving quadruple immunosuppression
with anti-interleukin-2 receptor antibodies. Transplantation 2008; 85 (3): 411.
[52] Held P, Kahan B, Hunsicker L, et al. The impact of HLA mismatches on the survival
of first cadaveric kidney transplants. N Engl J Med 1994; 331 (12): 765.
[53] Gjertson D, Terasaki P, Takemoto S, Mickey M. National allocation of cadaveric kid‐
neys by HLA matching. Projected effect on outcome and costs. N Engl J Med 1991;
324 (15): 1032.
[54] Takemoto S, Terasaki P, Gjertson D, Cecka J. Twelve years' experience with national
sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000;
343 (15): 1078.
[55] Schnitzler M, Hollenbeak C, Cohen D, et al. The economic implications of HLA
matching in cadaveric renal transplantation. N Engl J Med 1999; 341 (19): 1440.
[56] Gillich M, Heimbach D, Schoeneich G, Müller S, Klehr H. Comparison of blood
group versus HLA-dependent transplantation and its influence on donor kidney sur‐
vival. Nephrol Dial Transplant 2002; 17 (5): 884.
[57] Su X, Zenios S, Chakkera H, Milford E, Chertow G. Diminishing significance of HLA
matching in kidney transplantation. Am J Transplant 2004; 4 (9): 1501.
[58] Corte G, Damiani G, Calabi F, Fabbi M, Bargellesi A. Analysis of HLA-DR polymor‐
phism by two-dimensional peptide mapping. Proc Natl Acad Sci 1981; 78 (1): 534.
[59] Doxiadis I, de Fijter J, Mallat M, et al. Simpler and equitable allocation of kidneys
from postmortem donors primarily based on full HLA-DR compatibility. Transplan‐
tation 2007; 83 (9): 1207.
[60] Vereerstraeten P, Abramowicz D, Andrien M, Dupont E, De Pauw L, Kinnaert P. Al‐
location of cadaver kidneys according to HLA-DR matching alone would result in
optimal graft outcome in most recipients. Transplant Proc 1999; 31 (1-2): 739.
Current Issues and Future Direction in Kidney Transplantation366
[61] Ashby V, Port F, Wolfe R, et al. Transplanting Kidneys Without Points for HLA-B
Matching: Consequences of the Policy Change. Am J Transplant 2011; 11: 1712.
[62] Frohn C, Fricke L, Puchta J-C, Kirchner H. The effect of HLA-C matching on acute
renal transplant rejection. Nephrol Dial Transplant 2001; 16: 355.
[63] Takemoto S, Port F, Claas F, Duquesnoy R. HLA Matching for kidney transplanta‐
tion. Hum Immunol 2004; 65: 1489.
[64] Wake C, Long E. Allelic polymorphism and complexity of the genes for HLA-DR β-
chains—direct analysis by DNA–DNA hybridization. 1982.
[65] Patel R, Terasaki P. Significance of the positive crossmatch test in kidney transplanta‐
tion. N Engl J Med 1969; 280 (14): 735.
[66] Bryan C, Martinez J, Muruve N, et al. IgM antibodies identified by a DTT-ameliorat‐
ed positive crossmatch do not influence renal graft outcome but the strength of the
IgM lymphocytotoxicity is associated with DR phenotype. Clin Transplant 2001; 15
(Suppl 6): 28.
[67] Mulley W, Kanellis J. Understanding crossmatch testing in organ transplantation: A
case-based guide for the general nephrologist. Nephrology 2011; 16: 125.
[68] Gebel H, Bray R. Laboratory assessment of HLA antibodies circa 2006: making sense
of sensitivity. Transplant Revs 2006; 20 (4): 189.
[69] Eng H, Bennett G, Chang S, et al. Donor HLA Specific Antibodies Predict Develop‐
ment and Define Prognosis in Transplant Glomerulopathy. Hum Immunol 2011.
[70] Le Bas-Bernardet S, Hourmant M, Valentin N, et al. Identification of the antibodies
involved in B-cell crossmatch positivity in renal transplantation. Transplantation
2003; 75 (4): 477.
[71] Garovoy M, Bigos M, Perkins H, Colombe B, Salvatierra O. A high technology cross‐
match technique facilitating transplantation. Transplant Proc 1983; XV: 1939.
[72] Limaye S, O'Kelly P, Harmon G, et al. Improved graft survival in highly sensitized
patients undergoing renal transplantation after the introduction of a clinically vali‐
dated flow cytometry crossmatch. Transplantation 2009; 87 (7): 1052.
[73] Karpinski M, Rush D, Jeffery J, et al. Flow cytometric crossmatching in primary renal
transplant recipients with a negative anti-human globulin enhanced cytotoxicity
crossmatch. J Am Soc Nephrol 2001; 12 (12): 2807.
[74] Schlaf G, Pollok-Kopp B, Manzke T, Schurat O, Altermann W. Novel solid phase-
based ELISA assays contribute to an improved detection of anti-HLA antibodies and
to an increased reliability of pre- and post-transplant crossmatching. NDT Plus 2010;
3: 527.
The Evolution of HLA-Matching in Kidney Transplantation
http://dx.doi.org/10.5772/54747
367
[75] Kao K, Scornik J, Small S. Enzyme-linked immunoassay for anti-HLA antibodies-an
alternative to panel studies by lymphocytotoxicity. Transplantation 1993; 55: 192.
[76] Gibney E, Cagle L, Freed B, Warnell S, Chan L, Wiseman A. Detection of donor-spe‐
cific antibodies using HLA-coated microspheres: another tool for kidney transplant
risk stratification. Nephrol Dial Transplant 2006; 21 (9): 2625.
[77] Muro M, Llorente S, Gónzalez-Soriano M, Minguela A, Gimeno L, Alvarez-López M.
Pre-formed donor-specific alloantibodies (DSA) detected only by luminex technology
using HLA-coated microspheres and causing acute humoral rejection and kidney
graft dysfunction. Clin Transpl 2006: 379.
[78] Lee P, Ozawa M. Reappraisal of HLA antibody analysis and crossmatching in kidney
transplantation. Clin Transplant 2007: 219.
[79] Eng H, Bennett G, Tsiopelas E, et al. Anti-HLA donor-specific antibodies detected in
positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant
2008; 8 (11): 2335.
[80] Lefaucheur C, Loupy A, Hill G, et al. Preexisting donor-specific HLA-antibodies pre‐
dict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
[81] Lefaucheur C, Suberbielle-Boissel C, Hill G, et al. Clinical relevance of preformed
HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8
(2): 324.
[82] Ziemann M, Schonemann C, Bern C, et al. Prognostic value and cost-effectiveness of
different screening strategies for HLA antibodies prior to kidney transplantation.
Clin Transplant 2012; e-pub.
[83] Cantarovich D, De Amicis S, Aki A, et al. Posttransplant donor-specific anti-HLA an‐
tibodies negatively impact pancreas transplantation outcome. Am J Transplant 2011;
11: 2737.
[84] Ntokou I-SA, Iniotaki A, Kontou E, et al. Long-term follow up for anti-HLA donor
specific antibodies postrenal transplantation: high immunogenicity of HLA class II
graft molecules. Transplant Int 2011; 24: 1084.
[85] Wiebe C, Gibson I, Blydt-Hansen T, et al. Evolution and clinical pathologic correla‐
tions of de novo donor-specific HLA antibody post kidney transplant. Am J Trans‐
plant 2012; 12: 1157.
[86] Lefaucheur C, Loupy A, Hill G, et al. Preexisting donor-specific HLA antibodies pre‐
dict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21 (8): 1398.
[87] Mujtaba M, Goggins W, Lobashevsky A, et al. The strength of donor-specific anti‐
body is a more reliable predictor of antibody-mediated rejection than flow cytometry
crossmatch analysis in desensitized kidney recipients. Clin Transplant 2011; 25 (1):
E96.
Current Issues and Future Direction in Kidney Transplantation368
[88] Yabu J, Higgins J, Chen G, Sequeira F, Busque S, Tyan D. C1q-fixing human leuko‐
cyte antigen antibodies are specific for predicting transplant glomerulopathy and late
graft failure after kidney transplantation. Transplantation 2011; 91 (3): 342.
[89] Sutherland S, Chen G, Sequeira F, Lou C, Alexander S, Tyan D. Complement-fixing
donor-specific antibodies identified by a novel C1q assay are associated with allog‐
raft loss. Pediatr Transplantation 2012; 16: 12.
[90] Hoshino J, Kaneku H, Everly M, Greenland S, Terasaki P. Using donor-specific anti‐
bodies to monitor the need for immunosuppression. Transplantation 2012; 93: 1173.
[91] Organ Transplantation from Deceased Donors: Consensus Statement on Eligibility
Criteria and Allocation Protocols, 2011.
[92] Gaston R, Ayres I, Dooley L. Racial equity in renal transplantation. JAMA: the jour‐
nal of the … 1993.
[93] Smits JM, van Houwelingen HC, De Meester J, Persijn GG, Claas FH. Analysis of the
renal transplant waiting list: application of a parametric competing risk method.
Transplantation 1998; 66 (9): 1146.
[94] Duquesnoy RJ. Clinical usefulness of HLAMatchmaker in HLA epitope matching for
organ transplantation. Current Opinion in Immunology 2008; 20 (5): 594.
[95] Duquesnoy RJ, Marrari M. Correlations between Terasaki’s HLA class I epitopes and
HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens. Tissue Antigens
2009; 74 (2): 117.
[96] Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA. Epitope specificity of HLA
class I alloantibodies. I. Frequency analysis of antibodies to private versus public spe‐
cificities in potential transplant recipients. Human Immunology 1994; 39 (4): 272.
[97] Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-
specific antibodies in renal transplantation: contraindication vs. risk. American jour‐
nal of transplantation : official journal of the American Society of Transplantation
and the American Society of Transplant Surgeons 2003; 3 (12): 1488.
[98] Lobashevsky AL, Senkbeil RW, Shoaf JL, et al. The number of amino acid residues
mismatches correlates with flow cytometry crossmatching results in high PRA renal
patients. Human Immunology 2002; 63 (5): 364.
[99] Duquesnoy RJ. HLAMATCHMAKER: a molecularly based donor selection algorithm
for highly alloimmunized patients. Transplantation proceedings 2001; 33 (1-2): 493.
[100] Claas F, Witvliet M, Duquesnoy R, Persijn G, Doxiadis I. The acceptable mismatch
program as a fast tool for highly sensitized patients awaiting a cadaveric kidney
transplantation: short waiting time and excellent graft outcome. Transplantation
2004; 78 (2): 190.
[101] Duquesnoy RJ, Takemoto S, de Lange P, et al. HLAmatchmaker: a molecularly based
algorithm for histocompatibility determination. III. Effect of matching at the HLA-
The Evolution of HLA-Matching in Kidney Transplantation
http://dx.doi.org/10.5772/54747
369
A,B amino acid triplet level on kidney transplant survival. Transplantation 2003; 75
(6): 884.
[102] Claas FHJ, Doxiadis IIIN. Human leukocyte antigen antibody detection and kidney
allocation within Eurotransplant. Human Immunology 2009; 70 (8): 636.
[103] Gore SM, Bradley, Benjamin A. Renal transplantation : sense and sensitization. Stras‐
bourg Dordrecht; Boston: Council of Europe; Kluwer Academic Publishers, 1988.
[104] Do Nguyen H, Fidler, S, Irish, A, D'Orsogna, L, Christiansen, FT, Martinez, P, Lim,
W. The Idenfication of Acceptable HLA-Mismatches Improves Transplant Potential
of Highly-Sensitised Renal Transplant Recipients: Sir Charles Gairdner Hospital,
Royal Perth Hospital, University of Western Australia, 2012.
[105] Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pre‐
transplant donor-specific HLA antibodies detected by single-antigen flow-beads.
Transplantation 2009; 87 (11): 1681.
[106] Klouda P, Corbin S, Ray T, Rogers C, Bradley B. Renal transplantation in highly sen‐
sitized pati... [Clin Transpl. 1990] - PubMed - NCBI. Clinical transplantation 1990: 69.
[107] Opelz G. Five-year results of renal transplantation in highly sensitized recipients.
Collaborative Transplant Study. Transplant international : official journal of the Eu‐
ropean Society for Organ Transplantation 2007; 9 (Suppl 1): S16.
[108] Tardif GN, McCalmon RT. SEOPF high-grade HLA match algorithm: effective kid‐
ney sharing using ROP trays with HLA matching for highly sensitized patients.
Transplantation proceedings 1997; 29 (1-2): 1406.
Current Issues and Future Direction in Kidney Transplantation370
